Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

Publisher： Karger

E-ISSN： 1423-0232|84|5|255-264

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.5, 2013-02, pp. : 255-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 41-47

Karger

Access to resources Recommend Favorite

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

By Nuijten Mark J.C. Aultman Rick Carpeño Javier de Castro Vergnenègre Alain Chouaid Christos Walzer Stefan Siebert Uwe

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2193-2201

Informa Healthcare

Access to resources Recommend Favorite

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Case Reports in Oncology, Vol. 9, Iss. 2, 2016-08 ,pp. : 474-480

Karger

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3024-3031

John Wiley & Sons Inc

Access to resources Recommend Favorite